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Abstract
Monoclonal antibodies (mAbs) are well-established therapeutics, as evidenced by the large number of Food and Drug Administration-
approved mAbs for the treatment of cancers, and inﬂammatory or autoimmune diseases, and for the prevention and treatment of solid
organ transplant rejection. Although, in many cases, mAbs have improved patient survival, they are also associated with an increased
incidence of opportunistic infections. We review here the current and next generation of mAbs and the risks that infectious disease
specialists should be aware of.
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Introduction
The ﬁrst generation of monoclonal antibody (mAb) thera-
peutics, produced from mouse hybridomas, achieved little
clinical success, because of an inability to reduce their high
immunogenicity. Most therapeutic mAbs in development
today are chimeric or humanized to reduce immunogenicity.
More recently, fully human antibodies have been generated
by using transgenic animals or phage display technology in
cell lines of mammalian and non-mammalian origin, and fusion
proteins with Fc fragments from human IgGs have been cre-
ated (see Table 1 for nomenclature and Fig. 1 for struc-
tures). In addition to mAbs with favourably altered binding
afﬁnities, customized mAbs that have enhanced effector func-
tion (e.g. antibody-dependent cellular cytotoxicity and com-
plement-dependent cytotoxicity) are possible. A thorough
preclinical safety evaluation of these mAbs is very important,
owing to the increasing complexity of antibody engineering
aspects and the variability induced by the diversity of recom-
binant production cell systems. Furthermore, the longer half-
lives of mAbs than of traditional small molecule drugs lead
to further safety considerations.
Concerns arising from target-biology-related toxicities
have been highlighted by recent experiences with two ther-
apeutic mAbs, natalizumab (anti-a4-integrin) and TGN1412
(anti-CD28). Natalizumab for the treatment of multiple
sclerosis and Crohn disease was recalled from the market
because it was associated with an increased frequency of
JC virus reactivation and progressive multifocal leukoence-
phalopathy (PML) [1], a topic that is reviewed by Khalili
et al. in this issue of the journal. The Food and Drug
Administration approved the return of natalizumab to the
market, subject to a special restricted distribution pro-
gramme following a comprehensive review of a large num-
ber of patients. Similarly, when it was ﬁrst used in humans,
administration of TGN1412, a super-agonist mAb, to six
healthy volunteers led to devastating toxicity caused by
massive activation of T-cells [2]. It can be deduced from
the above examples that mAbs with immunomodulatory
properties have the potential to induce unexpected toxici-
ties. We will focus here on mAbs with immunosuppressive
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activity, which are likely to have the highest risk of causing
infectious complications.
Monoclonal Antibodies
The international ImMunoGeneTics information system has
developed a web database of mAbs with clinical indications
(accessible at http://www.imgt.org/mAb-DB/index). As of 26
May 2011, it listed 63 murine, 31 chimeric, 149 humanized,
one mixed (chimeric light chain, humanized heavy chain) and
98 human mAbs: of these, 34 are currently marketed.
Among them, the subset of mAbs with immunosuppressive
activity has been developed primarily to prevent transplant
rejection or treat autoimmune disorders. The mechanisms of
these mAbs are diverse, but all target speciﬁc proteins on
the T-lymphocyte or B-lymphocyte surface. Table 2 gives a
summary of all mAbs that are currently marketed or under
development; the following sections will separately discuss
these two categories. Although they are generated with dif-
ferent technologies, their functional similarity to mAbs have
led us to include in this review fusion proteins containing the
constant fragment (Fc) from human IgG1 (hFcc1) (summa-
rized in Table 3), mAbs used for radioimmunotherapy, and
TABLE 1. Monoclonal antibody nomenclature rules
Source identiﬁer inﬁxes preceding
the -mab sufﬁx stem
General disease
state subclass
-a- = rat Viral: -vir-
-e- = hamster Bacterial: -bac-
-i- = primate Immune: -lim-
-o- = mouse Infectious lesions: -les-
-xi- = chimera = human constant regions and Cardiovascular: -cir-
Murine variable regions (still elicit human
anti-murine antibody (HAMA))
Tumours:
Macaque variable regions (Primatized) Colon cancers: -col-
-zu- = humanized or hyperchimeric (human
constant and variable regions but murine
complementarity-determining regions (CDRs))
Melanoma: -mel-
-u- = fully human Mammary: -mar-
Transgenic animals producing human antibody
repertoires
Testis: -got-
In vitro production of human mAbs Ovary: -gov-
Lower molecular weight antibody-based binding sites Prostate cancer: -pr(o)-
Single-chain variable fragment (scFv) miscellaneous: -tum-
In order to create a unique name, a distinct, compatible syllable should be
selected as the starting preﬁx. The order for combining the key elements is as
follows: inﬁx representing the target disease state, source of the product, and ‘-
mab’ as a sufﬁx. When a target or disease inﬁx stem is combined with the
source stem for chimeric monoclonal antibody, the last consonant of the target/
disease syllable is dropped. These modiﬁcations were deemed necessary to facil-
itate pronunciation of the resultant designation. If the product is radiolabelled
or conjugated with another chemical, such as a toxin, identiﬁcation of this con-
jugate is accomplished by use of a separate, second word or other acceptable
chemical designation. For monoclonals conjugated to a toxin, the ‘-tox’ stem
must be included as part of the name selected for the toxin; for radiolabelled
products, the word order is: name of the isotope, element symbol, isotope
number, and name of the monoclonal antibody. A separate, distinct name must
be assigned to any linker/chelator used to conjugate the monoclonal antibody to
a toxin or isotope, or for pegylated monoclonal antibodies.
FIG. 1. Antibody structure (a), generations of antibody technology (b), and pharmacodynamics of monoclonal antibodies (mAbs) and mAb deriv-
atives (c). ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; CDR, complementarity-determining
region; scFc, single-chain variable fragment.
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TABLE 2. Summary of current and next-generation monoclonal antibodies (mAbs) with immunosuppressive activity according
to structure and target antigen(s)
Target antigens Brand name (trade name) Structure References
Soluble Complement component C5 Eculizumab/5G1.1 (Soliris) Humanized glycosylated hybrid IgG2–IgG4j [47]
TNF-a Inﬂiximab/chimeric A2 (cA2) (Remicade) Chimeric IgG1j [19]
Adalimumab/D2E7 (Humira; Trudexa) Fully human scFv IgG1j
Certolizumab pegol/CDP870 (Cimzia) Pegylated Fab¢ fragment of humanized IgG1
Afelimomab F(ab¢)2 fragment of a murine mAb
Golimumab/CNTO148 (Simponi) Human IgG1j
Nerelimomab/CDP571 Murine
IgE Omalizumab (Xolair) Humanized IgG1j [51]
IFN-c Fontolizumab Humanized IgG1 [52]
TGF-b1/3 Fresolimumab/GC-1008 Human IgG4 [53]
Metelimumab/CAT-192 Human IgG4 [54]
Lerdelimumab/CAT-152 Human IgG4
IL-1b Canakinumab/ACZ885 (Ilaris) Human IgG1 [55]
IL-4 Pascolizumab/SB 240683 Humanized IgG1 [56]
IL-5 Mepolizumab/SB-240563 Humanized IgG1 [57]
Reslizumab/SCH 55700 (Cinquil) Human–rat IgG4 [58]
IL-12 and IL-23 (p40 subunit) Briakinumab/ABT-874 Human IgG1j [59]
Ustekinumab/CNTO 1275 (Stelara) Human IgG1
IL-17A Secukinumab/AIN-457 Human IgG1j
CCL11/eotaxin Bertilimumab Human [60]
Membrane CD126/IL-6R Tocilizumab (Actemra) Humanized IgG1j [50]
Atlizumab Humanized IgG1 [61]
CD2 Siplizumab/MEDI-507 Humanized IgG1j [62]
CD3 Muromonab-CD3 (Orthoclone OKT3) Mouse IgG2a [30]
Otelixizumab/TRX4 Humanized IgG1k
Teplizumab/MGA031/hOKT3c1(Ala-Ala) Non-activating humanized IgG1 altered to
prevent binding to the Fcc receptor
Visilizumab (Nuvion) Humanized mutated IgG2 characterized by
lack of binding to Fcc receptorss
CD4 Clenoliximab Macaque Fv/human Fcc4 (Primatized)
chimeric
[63]
Keliximab/IDEC CE9.1 Macaque Fv/human Fc c1 (Primatized)
chimeric
[64]
Zanolimumab/HuMax-CD4 Human IgG1j [65]
CD5/Ly-1 Zolimomab aritox/H65 Murine IgG1 ricin A-chain immunoconjugate [66]
CD11a/aLb2 integrin/LFA-1 Efalizumab (Raptiva, formerly Xanelim) Humanized IgG1j [45]
Odulimomab Murine IgG1 [67]
CD19 SAR-3419 Humanized IgG1 conjugated to the
maytansine derivative DM4
NA
CD20 type I mAbs stabilize
CD20 on lipid rafts, leading
to stronger C1q binding, potent
induction of CDC, and low levels
of direct cell death
Type II mAbs do not stabilize
CD20 in lipid rafts, exhibit reduced
binding to C1q, induce lower levels
of CDC, but induce potent direct
cell death
Rituximab/chimeric 2B8 (IDEC-C2B8)
(Rituxan, MabThera) (type I)
Chimeric IgG1j [68]
Ocrelizumab/PRO70769 (type I) Humanized IgG1 [69]
Ofatumumab/2F2/HuMax-CD20 (Arzerra)
(type I)
Humanized IgG1j [70]
Veltuzumab/IMMU-106/hA20 (type I) Humanized IgG1j [71]
Afutuzumab/GA101 (type II) Humanized IgG1 with glycol-engineered Fc
portion
[72]
Tositumomab (type II) Murine IgG2a; the
131I conjugate (Bexxar)
is used for radioimmunotherapy
[73]
Ibritumomab tiuxetan (MXDPTA)/IDEC
Y2B8 (Zevalin)
Murine IgG1j; the
90Y conjugate is used for
radioimmunotherapy
[74]
CD22 Bectumomab/IMMU-LL2 Murine IgG2a [75]
Epratuzumab/hLL2/IMMU-102 (Lymphocydeª) Humanized IgG1 [48]
Inotuzumab Humanized IgG4; ozogamicin conjugate
(CMC-544)
[76]
BL22/CAT-3888 Fv fused to a truncated form of Pseudomonas
exotoxin253–264/381–613 (PE38)
[3]
Moxetumomab pasudotox/CAT-8015/HA22
CD23 Lumiliximab/IDEC-152 Macaque Fv/human Fcc1 (Primatized) [77]
CD25/IL-2 receptor Daclizumab (Zenapax) Humanized IgG1j [31]
Basiliximab (Simulect) Chimeric murine/human IgG1j
Inolimomab/BT563 Murine IgG1
LMB-2 Anti-Tac Fv fused to a truncated form of
Pseudomonas exotoxin253–264/381–613 (PE38)
[3]
CD30/Ki-1 Ag SGN30 Chimeric murine/human IgG1 [78]
MDX-060 Human IgG1j [79]
Brentuximab/cAC10/SGN-35 Chimeric IgG1j; brentuximab vedotin
(Adcetris) is chemically conjugated to
monomethylauristatin E
[80]
CD33 Gemtuzumab Humanized IgG4. The ozogamicin conjugate
(Mylotarg) was the ﬁrst drug–mAb
conjugate, approved by FDA in 2000, but
Pﬁzer announced a voluntary withdrawal in
the USA on June 2010 because of severe
veno-occlusive disease
[81]
Lintuzumab/HuM195 (Zamyl) Humanized IgG1 [82]
CD40 Dacetuzumab/SGN-40 Humanized IgG1 [83]
CD49d/a4 integrin
(both a4b1 and a4b7)/VLA-4
Natalizumab (Tysabri, Antegren) Humanized IgG4j [84]
Vedolizumab/MNL-0002 Humanized IgG1 [85]
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antibody–drug conjugates (ADCs) (so-called ‘immunotoxins’)
[3] with immunosuppressive activity. Immunosuppressive
polyclonal antibodies, non-antibody-based fusion proteins
(e.g. denileukin diftitox [4]) and non-antibody ligands for
immunological receptors (e.g. anakinra [5]) are beyond the
scope of this review. Similarly, we will not review here mAbs
used for the treatment of solid cancers and antiangiogenic
mAbs, which are not directly immunosuppressive.
The current generation
Anti-CD20 mAbs. Rituximab (Rituxan; Genentech, San Fran-
cisco, CA, USA) is a chimeric anti-CD20 antibody that is
being increasingly used for the treatment of autoimmune dis-
eases and, in combination with polychemotherapy, of B-cell
non-Hodgkin lymphomas. In combination with intravenous
immunoglobulins and plasmapheresis, rituximab is also used
for desensitization against donor-speciﬁc anti-HLA antibodies
or isoagglutinins in incompatible transplantation, and for
treatment of donor-speciﬁc anti-HLA antibody-mediated
rejection (antibody-mediated rejection (AMR)).
Gurcan et al. [6] reviewed the use of rituximab in 92 stud-
ies involving 1197 patients with autoimmune diseases (sys-
temic lupus erythematosus, idiopathic thrombocytopenic
purpura, anti-neutrophil cytoplasmic antibody-associated vas-
culitis, Grave’s disease, autoimmune haemolytic anaemia,
pemphigus vulgaris, haemophilia A, cold agglutinin disease,
Sjogren’s syndrome, graft vs. host disease, thrombotic
thrombocytopenic purpura, cryoglobulinaemia, IgM-mediated
neuropathy, multiple sclerosis, neuromyelitis optica, idio-
pathic membranous nephropathy, dermatomyositis, and
opsoclonus myoclonus), and concluded that systemic infec-
tion still remains a major concern. Recently, the Spanish
BIOGEAS Study Group reported that, in patients treated
with more than two courses of rituximab, the crude rate of
severe infection was 226.4 events/1000 person-years [7].
Like natalizumab and efalizumab, rituximab has also been
associated with PML in large case series [8].
Genberg et al. [9] conducted a prospective, double-blind,
multicentre randomized trial comparing 68 kidney transplant
patients treated with rituximab with 68 placebo-controlled
patients (administered along with tacrolimus, mycophenolate
mofetil (MMF), and steroids), and reported no statistically
signiﬁcant difference in the overall incidence of cytomegalovi-
rus, BK virus, bacterial or fungal infections between the two
groups.
A number of other case reports and studies have raised
concerns regarding potential complications of rituximab use
for AMR. Kamar et al. [10] compared infectious complica-
tions among 77 rituximab-treated patients (2–8-h course for
AMR episodes) with 902 retrospectively reviewed control
patients. Although the rate of infection was similarly high in
both groups (45.5% rituximab-treated vs. 53.9% controls),
the mortality rate was signiﬁcantly higher in the rituximab
group (9.1% vs. 1.6%). Other reports have documented cases
of late-onset Pneumocystis jiroveci pneumonia [11], cryptogenic
organizing pneumonia [12] and JC virus-associated PML [13]
in patients treated with rituximab in the post-transplant per-
iod. In haematological patients, an increased risk of hepati-
TABLE 2. (Continued)
Target antigens Brand name (trade name) Structure References
CD52 Alemtuzumab/Campath-1H (MabCampath) Humanized IgG1j [86]
CD56 Lorvotuzumab mertansine Humanized IgG1 conjugated to the
maytansine derivative DM1
[87]
CD62L/L-selectin Aselizumab Humanized IgG4 [88]
CD80 Galiximab/IDEC-114 Chimeric human Fc/macaque Fv
(Primatized) IgG1k
[89]
CD147/basigin Gavilimomab/ABX-CBL Murine [90]
CD154/CD40L Ruplizumab (Antova) Humanized IgG1j [91]
CD194/CCR4 Mogamulizumab/KW-0761/AMG-761 Defucoylated humanized IgG1 [92]
CD257/BLyS Belimumab (Benlysta, LymphoStat-B) Human IgG1k [49]
HLA-DR Apolizumab/Hu1D10 Humanized IgG1 [93]
Lym-1 (Oncolym) Humanized IgG1 [94]
1D09C3 Human IgG4 [94]
HL2434P (IMMU-114) Humanized IgG4 [95]
CDC, complement-dependent cytotoxicity; FDA, Food and Drug Administration; IFN, interferon; IL, interleukin; LFA-1, leukocyte function-associated antigen 1; scFv, single-
chain variable fragment; TGF, transforming growth factor; TNF, tumour necrosis factor.
TABLE 3. Current and next-generation hFcc1 fusion pro-
teins (-cept) with immunosuppressive activity
Target antigen Structure References
B7-1 (CD80), B7-2
(CD86)
Abatacept/CTLA4-Ig/BMS-188667
(Orencia)
[42]
Belatacept/LEA29Y [96]
TACI-Ig Atacicept/BLyS/APRIL-Ig [97]
TNF-a-Ig Etanercept/TNFR-Ig (Enbrel) [19]
Pegsunercept/pegylated TNFR-Ig
CD58/LFA-3-Ig Alefacept (Amevive) [46]
IL-1R/IL-1Rap-Ig Rilonacept (Arcalyst) [98]
BLyS, B-lymphocyte stimulator; CTLA4, cytotoxic T-lymphocyte antigen 4; IL,
interleukin; IL-1R, interleukin-1 receptor; TNF, tumour necrosis factor.
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tis B virus reactivation in occult carriers has been shown
[14], with case reports also suggesting ﬂares of hepatitis C
virus (HCV) [15]. Other complications seen in both rheuma-
tological and haematotological patients include late-onset
neutropenia [16] and hypogammaglobulinaemia [17], which
are usually associated with marked B-lymphocyte depletion
and severe infections.
After intravenous delivery of rituximab, CD27+ memory
B-cells show slow and delayed repopulation, and the level of
these cells remained signiﬁcantly reduced (<50%) as com-
pared with baseline values for >2 years [18]. Expansion of
functionally immature B-cells and decreased memory B-cells
may contribute to an immunodeﬁcient state in patients
recovering from rituximab-mediated B-cell depletion, particu-
larly with repeated treatment.
Anti-tumour necrosis factor (TNF)-a mAbs. Inﬂiximab (Remicade;
Centocor, Horsham, PA, USA) is a chimeric mAb that
targets both soluble and membrane-bound forms of TNF-a.
Although the precise mechanism of action remains unclear,
at least two things are known: (i) inﬂiximab binds and
neutralizes TNF-a; and (ii) it induces apoptosis in active T-cells
[19]. Initially approved by the Food and Drug Administration
for use in treating Crohn disease, inﬂiximab has since been
approved for use in ulcerative colitis, rheumatoid arthritis,
ankylosing spondylitis, and plaque psoriasis. The success of
inﬂiximab prompted the manufacture and marketing of new-
generation anti-TNF-a mAbs, such as the fully human goli-
mumab (Simponi), the scFv adalimumab (Humira), the fusion
protein etanercept (Enbrel), and the pegylated (extended
half-life) certolizumab pegol (Cimzia). Interestingly, certo-
lizumab pegol has been associated with signiﬁcantly higher
odds of serious infections than etanercept, adalimumab, goli-
mumab, and inﬂiximab [20], but larger series are required to
establish the actual risks.
Reactivation of latent tuberculosis infection is well rec-
ognized as an adverse event associated with anti-TNF-a
therapy. The risk of reactivation is higher for patients
receiving anti-TNF-a mAb therapy than for those receiving
fusion protein therapy [21]. The increased risk with early
anti-TNF-a treatment and the absence of correct chemo-
prophylactic treatment favour the reactivation of latent
tuberculosis. Reactivation represents a diagnostic challenge,
as anergy may inﬂuence screening performance of the
tuberculin skin test and interferon-c release assays in
patients on anti-TNF-a therapy. Conversely, the potential
for false-positive tuberculin skin test and interferon-c
release assay results must be considered, as treatment for
latent tuberculosis infection may be associated with signiﬁ-
cant morbidity.
In a study by Charpin et al. [22] of 21 patients whose hep-
atitis B virus serology suggested carrier status, anti-TNF-a
treatment appeared to be safe during a limited follow-up
period of 3 years, but about 30% of the patients developed
signiﬁcant lowering of antibody titres, which may become
relevant during long-term follow-up.
Anti-CD3 mAbs. Muromonab-CD3 (also known as OKT3) is a
murine IgG2a antibody directed at the -chain of CD3 that
was ﬁrst used in the setting of renal transplant induction
therapy in the 1980s: it was shown to be effective in the
treatment of acute allograft rejection. Its popularity contin-
ued to grow when it was unequivocally shown to signiﬁcantly
decrease the percentage of acute rejections of cadaveric
transplants as compared with conventional high-dose steroid
therapy. However, because of its numerous side effects (ex-
pecially a systemic inﬂammatory response secondary to cyto-
kine release syndrome after the ﬁrst dose, owing to massive
lysis of opsonized T-cells) and better-tolerated alternatives,
its use declined, and OKT3 was recently removed from both
the US and EU markets. More rarely, OKT3 treatment led
to aseptic meningitis or intragraft thrombosis. Also, because
OKT3 is a mouse mAb, patients typically developed anti-idio-
type and, more importantly, anti-murine antibodies in a time-
scale on the order of days, thus limiting its usefulness beyond
a single round of treatment.
Although OKT3 showed considerable success in reversing
acute rejection episodes for a variety of solid organ trans-
plants, especially in high-risk rejection patients, comparative
studies with next-generation therapies generally provided
alternatives with better empirical outcomes and reduced side
effects. OKT3 was most notably outperformed by anti-CD25
treatment in heart transplantation (equivalent cardiac allo-
graft survival outcomes), and by anti-thymocyte globulin
treatment, which demonstrated roughly equivalent short-
term graft outcomes in kidney (89% anti-thymocyte globulin
vs. 81% OKT3 1-year graft survival rates), lung (52% rabbit
anti-thymocyte globulin (RATG) vs. 34% OKT3 5-year sur-
vival outcomes) and liver transplantation. Its usage was spe-
ciﬁcally contraindicated in HCV-infected patients, because
OKT3 treatment was associated with worse outcomes
[23,24]. Other adverse events described were probably
caused by excessive immunosuppression. These included
increased rates of post-transplant lymphoproliferative disease
(PTLD) [25], fungal infections [26], and human cytomegalovi-
rus (HCMV) infections [27–29]. A number of humanized
OKT3 Fc variants have been developed (Table 2) to avoid
this issue of antigenicity, but cytokine release syndrome
remains a complication [30].
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Anti-CD25 mAbs. Two antibodies—basiliximab and dac-
lizumab—have been developed that selectively interact with
the a-subunit of the interleukin (IL)-2 receptor (CD25), thus
competitively inhibiting IL-2 binding and subsequently pre-
venting T-cell expansion [31].
Daclizumab, a humanized IgG1 mAb, was ﬁrst introduced
in 1998. Studies have demonstrated that, relative to placebo
controls, daclizumab treatment groups have had better graft
function (as measured by mean glomerular ﬁltration rate,
58 mL/min vs. 51 mL/min), comparable PTLD incidence [32],
and a reduced incidence of HCMV infection [33]. In addition
to renal applications, daclizumab has been used in liver, heart
and, to a lesser extent, lung transplants. Although daclizumab
has been widely used for more than a decade, it was discon-
tinued in the USA in September 2009, owing to the availabil-
ity of more popular alternatives and decreasing demand.
In 1997, Nashan et al. [34] published the results of a ran-
domized prospective trial with basiliximab induction com-
pared with placebo on a double-therapy background
(cyclosporin A and steroids). There were no signiﬁcant dif-
ferences in rates of infection or PTLD. In 2002, several stud-
ies demonstrated that two-dose basiliximab induction in liver
transplant patients was well tolerated and effective in reduc-
ing biopsy-proven acute rejection (BPAR) rates (35.1% basil-
iximab vs. 43.5% placebo at 6-month follow-up), although to
a lesser extent in HCV-positive cohorts [35]. In the setting
of HCV-seropositive individuals, Filipponi et al. [36] demon-
strated lower BPAR rates with normal steroid supplementa-
tion, but better patient survival without it. In this and other
studies, short-term HCV recurrence has been less prevalent
in treatment arms that are steroid-free [37,38].
Anti-CD52 mAbs. CD52 is a membrane glycoprotein of
unknown function that is especially highly expressed on lym-
phocytes (up to 5% of surface antigens), explaining the pow-
erful immunodepleting effect of anti-CD52 antibodies.
Campath-1H (also known as alemtuzumab) is the humanized
form of a murine anti-CD52 mAb (Campath-1G). Campath-
1G was used extensively to repress rejection of bone
marrow grafts, but immunogenicity and consequent dosing
limitations proved restrictive in the setting of solid organ
transplants. In 1999, Campath-1H trials showed that the
humanized IgG2b variant, with low-dose cyclosporin A mono-
therapy, successfully reversed acute rejection episodes in
renal transplant patients. Tan et al. [39] compared RATG (24
patients) with alemtuzumab (166 patients) on a background
of low-dose tacrolimus monotherapy. At 401-day follow-up,
alemtuzumab-treated patients had signiﬁcantly lower rates of
acute rejection (8.4% alemtuzumab vs. 29.2% RATG), with
no difference in HCMV infections or PTLD. The largest
randomized controlled trial was conducted by Margreiter
et al. [40] in 2008. A total of 131 kidney transplant patients
were randomized to alemtuzumab with delayed tacrolimus
or triple therapy (tacrolimus, MMF, steroids). At 1-year fol-
low up, the alemtuzumab arm showed slightly improved
BPAR rates (20% alemtuzumab vs. 32% control) and graft
survival (96% vs. 90%), but the incidence of HCMV infections
was also higher. The trend for a higher rate of HCMV infec-
tion is similar to what has been observed in haematological
patients receiving alemtuzumab for chronic lymphocytic leu-
kaemia or in the setting of conditioning before allogeneic ha-
ematopoietic stem cell transplantation [41]: it has also been
shown that systematic monitoring of HCMV viraemia and
early treatment of infection results in a favourable outcome
regarding HCMV reactivation.
The next generation
Recent advances in our understanding of transplant immunol-
ogy are encouraging the manufacture of a plethora of new
mAbs targeting co-stimulatory signals, cell surface receptors,
and novel protein constructs. A complete list is given in
Tables 2 and 3; here, we will brieﬂy discuss the most prom-
ising ones.
mAbs targeting co-stimulatory pathways. Activation of T-lym-
phocytes requires both antigen-speciﬁc (signal 1) and
co-stimulatory (signal 2) pathways. Naı¨ve T-cells contain the
CD28 receptor, to which CD80 and CD86 bind to induce
the co-stimulatory signal. Once T-cells become active, the
inhibitory molecule cytotoxic T-lymphocyte antigen 4
(CTLA4) is expressed to prevent further T-cell co-stimula-
tion. Immunosuppression targeting the co-stimulatory path-
way became available in 2005, when the CTLA4–IgG fusion
protein abatacept (Orencia; Bristol-Myers Squibb, Princeton,
NJ, USA) ﬁrst underwent clinical trials [42]. Shortly there-
after, a CTLA4–IgG fusion protein that is more speciﬁc for
CD80, belatacept (Bristol-Myers Squibb) proved itself as a
calcineurin inhibitor (CNI) replacement that does not com-
promise acute rejection rates [43]. Interestingly, belatacept
(CD28-CD80/86 blockade) in combination with basiliximab
(IL-2 blockade) did not affect regulatory T-cells in the long
term as compared with CNI regimens [44].
mAbs targeting adhesion molecules. Leukocyte function-associ-
ated antigen 1 (LFA-1) serves as an adhesion molecule in the
communication between antigen-presenting cells and T-lym-
phocytes. Efalizumab (Raptiva; Genentech), a humanized
LFA-1 IgG1 antibody, was initially approved for the treatment
of psoriasis in 2003. Vincenti et al. studied efalizumab treat-
ment in 38 kidney transplant recipients against a background
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of maintenance immunosuppression. Four groups of patients
were given biweekly injections of high-dose or low-dose ef-
alizumab with either full-dose cyclosporin, MMF and corti-
costeroids or half-dose cyclosporin, sirolimus and
corticosteroids. Although acute rejection rates remained low
at 6 months in all groups, 8% of patients in the group receiv-
ing high-dose efalizumab and high-dose CNIs experienced
early PTLD. However, efalizumab was voluntarily withdrawn
by Genentech in 2009, owing to an increased risk of PML
observed in patients being treated for psoriasis [45]. Alefa-
cept (Amevive; Astellas, Tokyo, Japan), an LFA-3–IgG1 fusion
protein, prevents the interaction of CD2 and LFA-3 binding
[46].
mAbs targeting complement factors. Eculizumab (Soliris; Alex-
ion, Cheshire, CT, USA) is a humanized mAb that speciﬁcally
binds complement 5, thereby inhibiting the formation of the
membrane attack complex and preventing cell lysis and
death. Eculizumab is currently only approved in the USA for
the treatment of paroxysmal nocturnal haemoglobinuria, but
Locke et al. recently reported a case of severe AMR in a kid-
ney transplant recipient that was successfully treated with
eculizumab in conjunction with plasmapheresis, intravenous
immunoglobulin, and rituximab. At least theoretically, ecu-
lizumab could be associated with increased risk of infections
caused by pathogens whose clearance is dependent on com-
plement-ﬁxing antibodies (e.g. Neisseria meningitidis and Strep-
tococcus pneumoniae) [47].
mAbs targeting B-lymphocytes. Epratuzumab (Immuno-medics,
Morris Plains, NJ, USA) targets the surface antigen CD22,
which, although not present on immature B-cells or plasma
cells, is expressed on certain differentiating B-cells.
Epratuzumab was originally developed for the treatment of
non-Hodgkin lymphoma, but has since been used to treat a
variety of autoimmune inﬂammatory disorders, most notably
systemic lupus erythematosus [48].
Belimumab (Human Genome Sciences, Rockville, MD, USA)
is a human mAb that targets and inhibits B-lymphocyte stimu-
lator, a vital B-cell surface protein survival factor. B-lympho-
cyte stimulator has two important signalling properties: (i)
preventing apoptosis; and (ii) stimulating differentiation to
plasma cells. By preventing this signalling, belimumab induces
apoptosis and prevents immunoglobulin production [49].
mAbs targeting serum cytokines or cytokine receptors. IL-6
exerts its immunomodulatory effects by enhancing T-cell
activation and differentiation by upregulating IL-2 receptors
and IL-2 production, inducing thymocyte proliferation and
thymic T-cell development, stimulating B-cell proliferation,
and activating acute-phase protein production. Tocilizumab
(Roche, San Francisco, CA, USA) is a humanized mAb that
binds the IL-6 receptor in both membrane-bound and soluble
forms, and consequently inhibits IL-6-mediated signalling. It is
principally used in the treatment of rheumatoid arthritis,
although it is being tested for use in other inﬂammatory
autoimmune disorders [50].
Conclusions
There has been an explosive growth of highly targeted
immunosuppressive mAbs directed against cytokines, recep-
tors, and complement factors. These mAbs will probably play
a more prominent role in the prevention and treatment of
allograft rejection and in the treatment of autoimmune disor-
ders and lymphoproliferative disorders. Understanding the
infective risks associated with such agents will be essential to
improve their use.
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